Alethine
DRACPC ID DRACPC0077
Active Ingredients Alethine
Description A disulfide agent that stimulates T and B-cell functions and exhibits anti-tumor and immunostimulant activity.
Synonyms Beta Alethine; Beta-alanyl-cysteamine Disulfide; BetaLT; Betathine; N,N'-(Dithiodiethylene)bis(3-aminopropionamide); Alethine
Type Small Molecule
Disease Lymphoma, Multiple myeloma
Classification
Amino acid and derivative
Structure Information
Molecular Formula C10H22N4O2S2
Molecular Weight 294.4
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name 3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide
InChI InChI=1S/C10H22N4O2S2/c11-3-1-9(15)13-5-7-17-18-8-6-14-10(16)2-4-12/h1-8,11-12H2,(H,13,15)(H,14,16)
InChI_Key WELIVEBWRWAGOM-UHFFFAOYSA-N
SMILES O=C(NCCSSCCNC(CCN)=O)CCN
External Codes
PubChem CID 69532
DrugBank Accession Number DB05800
NCI Thesaurus Code C2605
UNII LY583605Y8 GSRS
CAS 646-08-2
Drug approval
Drug indication
Investigated for use/treatment in blood (blood forming organ disorders, unspecified), lymphoma (unspecified), and multiple myeloma.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00006466 | Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma | Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition | Phase 1/2 | Treatment |
| NCT00007839 | Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma | Lymphoma | Phase 1/2 | Treatment |
| NCT00041379 | Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia | Lymphoma | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
